52-week high alert: Pharma stock hit upper circuit as it announces outstanding results; India's leading fund buys stake in it!

The stock has impressive ROCE of 172 per cent and ROE of 129 per cent  

The shares of Remus Pharmaceuticals Limited soared 4.99 per cent to hit a fresh 52-week high of Rs 2079.90 per share on NSE.  

For FY23 the company’s net sales zoomed by 82.16 per cent from last year to Rs 45.03 crore. The operating profit witnessed a significant increase of 145.11 per cent on YoY basis, amounting to Rs 10.54 crore. Furthermore, company’s net profit showed a massive jump of 147.81 per cent from FY22, reaching Rs 8.50 crore.  

  Remus Pharmaceuticals Limited has a robust ROCE of 172 per cent and ROE of 129 per cent. The company made an IPO of Rs 47.69 crore.   

Negen Capital Services Private Ltd made a bulk deal of 34,000 shares at Rs 1793.90 aggregating to Rs 6.09 crore. Negen Capital is owned by Neil Bahal, a well-known fund manager in the country. 

DSIJ offers a service 'Tiny Treasure' with recommendations for small-cap & micro-cap stocks based on research and analysis to help subscribers make informed investment decisions. If this interests you, then do download the service details pdf here

Remus is a cutting-edge pharmaceutical firm that is driven by forward-thinking and is dedicated to improving people's health by providing a wide range of high-quality, low-cost pharmaceutical goods. They continue to expand their product line of Active Pharmaceutical Ingredients and Finished Formulations in 40+ countries across the continents, backed by skilled scientists, state-of-the-art manufacturing facilities and global distributors.